IFIgnacio F. San Francisco

Ignacio F. San Francisco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ignacio F. San Francisco has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tabaquismo y tumores mayores de 2 centímetros son predictores de mortalidad en pacientes sometidos a nefro-ureterectomías por carcinoma de urotelio alto

    by Pablo A. Rojas, Juan Cristóbal Bravo, Héctor Gallegos, Álvaro Zúñiga, Ignacio San Francisco

    El gold estándar de manejo de los UTUC de pelvis y uréter proximal corresponde a la nefro-ureterectomía (NUR) y extracción en bloque con resección de uréter distal4 , que puede realizarse abierta o mínimamente invasiva. La NUR alcanza una sobrevida libre de recurrencia a 5 años de 75-84%5 , 6 y una sobrevida cáncer específica a 5 años de 78%5 . Raman et al.5 describieron factores pronósticos de mortalidad en una serie de NUR, destacando el estadio T patológico (HR 25,58, IC95% 9,854-66,445, p < 0,001) y el grado histológico (HR 1,697, IC95% 1,100-2,617, p = 0,017). La localización (uréter proximal o pelvis) y los ganglios positivos no afectarían la mortalidad a largo plazo5 .


  • Is Uro-oncological Surgery Safe During the COVID-19 Pandemic? Comparative Morbidity and Mortality in Patients Undergoing Surgery 2019-2020

    by Juan Cristóbal Bravo, Renato Navarro, P Rojas, Laura Hinrichs, Maximiliano Schalper, Alvaro Zuñiga, Ignacio San Francisco

  • Open Access

    Protective role of intravesical BCG in COVID-19 severity

    by Héctor Gallegos, Pablo A. Rojas, Francisca Sepúlveda, Álvaro Zúñiga, Ignacio F. San Francisco

    Objectives: To establish the role of BCG instillations in the incidence and mortality of COVID-19. Patients and methods: NMIBC patients in instillations with BCG (induction or maintenance) during 2019/2020 were included, establishing a COVID-19 group (with a diagnosis according to the national registry) and a control group (NO-COVID). The cumulative incidence (cases/total patients) and the case fatality rate (deaths/cases) were established, and compared with the national statistics for the same age group. T-test was used for continuous variables and Fisher's exact test for categorical variables. Results: 175 patients were included. Eleven patients presented CIS (11/175, 6.3%), 84/175 (48.0%) Ta and 68/175 (38.9%) T1. Average number of instillations = 13.25 ± 7.4. One hundred sixty-seven patients (95.4%) had complete induction. Forty-three patients (cumulative incidence 24.6%) were diagnosed with COVID-19. There is no difference between COVID-19 and NO-COVID group in age, gender or proportion of maintenance completed. COVID-19 group fatality rate = 1/43 (2.3%). Accumulated Chilean incidence 70–79 years = 6.3%. Chilean fatality rate 70–79 years = 14%. Conclusions: According to our results, patients with NMIBC submitted to instillations with BCG have a lower case-fatality rate than the national registry of patients between 70 and 79 years (2.3% vs. 14%, respectively). Intravesical BCG could decrease the mortality due to COVID-19, so instillation schemes should not be suspended in a pandemic.


  • Open Access

    Bladder squamous cell carcinoma in a pregnant woman: case report and review of the literature

    by Pablo A. Rojas, Cristián González, Gonzalo P. Mendez, Alejandro Majerson, Ignacio F. San Francisco

    Bladder tumors in pregnancy are extremely rare. No more than 50 cases have been published to date, including all histologic variants, and only three cases of bladder squamous cell carcinoma have been described. We present a clinical case of a 31-year-old woman with bladder squamous cell carcinoma in the second trimester of pregnancy. After a C-section at 30 weeks, we performed radical cystectomy with extended bilateral lymphadenectomy, hysterectomy and right oophorectomy. The Studer neobladder technique was performed for urinary tract reconstruction. Definitive pathology showed invasive bladder squamous cell carcinoma, Grade 2, with microscopic infiltration of the perivesical fat, negative margins, and 3/28 lymph nodes with carcinoma (pT3aN2M0). The patient underwent 18 months of surveillance after radical cystectomy, without recurrence by PET-CT. Bladder cancer in pregnant women is extremely rare but must be considered in those with recurrent gross hematuria and/or recurrent urinary tract infection. To our knowledge, this case involves the longest recurrence-free survival of a pregnant woman with squamous cell bladder cancer published thus far.


  • Open Access

    Acute liver failure and liver transplantation secondary to flutamide treatment in a prostate cancer patient

    by Pablo A. Rojas, Tomás G. Iglesias, Francisco Barrera, Gonzalo P. Mendez, Javiera Torres, Ignacio F. San Francisco


  • Open Access

    Priapism induced by use of tamsulosin: A case report and review of the literature

    by Marcelo Marconi, Pablo Pavez, Ignacio San Francisco, Paulette Narvaez

    Numerous medications have been associated to the development of priapism as an adverse reaction, the most common are intracavernosal vasoactive agents, antipsychotics and antidepressants. Alpha blockers, in particular tamsulosin which is widely used in different urological conditions, has been associated to priapism in only few case reports. We present the case of a healthy 45-year-old man who medicated himself with two doses of 0.4 mg of tamsulosin due to a renal colic with spontaneous passage of a 3 mm stone. Eight hours after the second tamsulosin dose the patient developed a persistent painful erection not associated to sexual stimulation that lasted for 6 hours. He was admitted to the emergency room, and after history taking and physical evaluation the diagnosis of ischemic priapism was made. The patient denied consumption of any other medication or drug during the last month, blood tests in particular hemogram were normal and no recent history of pelvic trauma was reported. To achieve detumescence, five boluses of 200 mcg of phenylephrine were injected directly in the corpora cavernosa, no further procedures were needed. In the follow-up the patient had no new priapism episodes and he reported no problems with erections in sexual intercourse. Tamsulosin is one of most indicated medications in urological general practice; though priapism has been rarely associated to its consumption the risk of this side effect exists, suggesting that patients should be counselled about it.


  • Open Access

    Score genético predice agresividad del cáncer de próstata.

    by Pablo Rojas, Paola Viviani, Viviana Montecinos, Yu Ting Zhou, Claudio Morales, Alejandro Godoy, Ignacio San Francisco

    Introducción: Establecer un score genético utilizando los polimorfismos de nucleótido único (SNPs) del gen RNAsel y regiones cromosómicas 8q24 y 17q12-24 en combinación con el antígeno específico de la próstata (PSA) para predecir la agresividad del cáncer de próstata (CaP).Pacientes y métodos: hombres con CaP tratados con prostatectomía radical. Se analizaron variables clínicas y patológicas: edad al diagnóstico, PSA al diagnóstico, el volumen tumoral (TV) y extensión extracapsular (ECE) según el TNM (tumour, node and metástasis) (ECE ≥T3) y score de Gleason. Desarrollamos un modelo de puntaje genético usando regresión logística multivariable.Resultados: se incluyeron 86 pacientes sometidos a prostatectomía radical. Edad promedio fue de 62 ± 7,5 años. El promedio de PSA fue de 11,3 ± 10,6 ng/mL. Treinta y un pacientes (36%) tuvieron ECE. La mediana del TV fue de 3,8 cc. Un PSA ≥ 10 ng/mL se asoció con una mayor tasa de ECE (p 1 SNP tienen mayor riesgo de ECE que los pacientes con ≤ 1 SNP (42% vs. 10,5%, p = 0,01), y los pacientes con ≥ 3 SNP tienen más TV que los pacientes con <3 SNP (60% vs. 32%, p = 0,015). Se crearon dos modelos de riesgo usando el número de SNP y PSA ≥ o <10 ng/mL para predecir ECE (sensibilidad 67% y especificidad 84%) y TV (sensibilidad 59% y especificidad 70%).Conclusiones: El score genético presentado en este estudio es una herramienta novedosa para predecir indicadores de agresividad del CaP, como ECE y TV.


  • Open Access

    Estilo de vida y agresividad del cáncer de próstata.

    by Pablo A Rojas, Claudia Hurtado, Viviana P Montecinos, Alejandro S Godoy, Ignacio F San Francisco

    Introducción: el objetivo de este estudio fue establecer una asociación entre diversas variables demográficas y epidemiológicas con la agresividad del cáncer de próstata (CaP).Métodos: pacientes diagnosticados con CaP respondieron una encuesta que incluye el nivel de educación, los factores de riesgo cardiovascular (FRCV), los antecedentes familiares (HF) de CaP, consumo de alcohol, tabaquismo y otros. Se utilizó análisis univariado y multivariado (AMV) para establecer si los factores mencionados anteriormente afectan las variables asociadas con la agresividad del CaP, como la edad al momento del diagnóstico, el índice de Gleason, los márgenes positivos (MP) y la metástasis óseas (MO), entre otras.Resultados: se incluyeron ciento setenta y dos hombres en el análisis. Los pacientes con HF fueron diagnosticados a edades más tempranas que los pacientes sin HF (55,73 vs 66,45 años, p = 0,0001). Los pacientes que beben tienen un mayor número de MP que los pacientes que no (15 vs 4 pacientes, p = 0,04). El AMV mostró que los pacientes que consumen alcohol y los que fuman (activos o suspendidos) tuvieron un mayor riesgo de MP (OR = 4,45 y 4,1, IC 95% 1,16-17,07 y 1,14-14,72, respectivamente, ambos p <0,05). Los pacientes con mayor nivel de educación presentaron un mayor riesgo de CaP confinado (OR = 3,42, IC 95% 1,392-8,434, p = 0,007).Conclusiones: los pacientes que consumen alcohol, fuman y tienen un menor nivel de educación presentaron un mayor riesgo de desarrollar CaP agresivo.

  • Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance

    by Ignacio F. San Francisco, Pablo A. Rojas, William C. DeWolf, Abraham Morgentaler

    Objective: To determine whether total testosterone and free testosterone levels predict disease reclassification in a cohort of men with prostate cancer ( PCa ) on active surveillance ( AS ). Patients and Methods: Total testosterone and free testosterone concentrations were determined at the time the men began the AS protocol. Statistical analysis was performed using Student's t ‐test and a chi‐squared test to compare groups. Odds ratios ( ORs ) with 95% confidence intervals ( CI s) were obtained using univariate logistic regression. Receiver–operator characteristic curves were generated to determine the investigated testosterone thresholds. K aplan– M eier curves were used to estimate time to disease reclassification. A C ox proportional hazard regression model was used for multivariate analysis. Results: A total of 154 men were included in the AS cohort, of whom 54 (35%) progressed to active treatment. Men who had disease reclassification had significantly lower free testosterone levels than those who were not reclassified (0.75 vs 1.02 ng/dL, P = 0.03). Men with free testosterone levels P = 0.032). Free testosterone levels <0.45 ng/dL were associated with a several‐fold increase in the risk of disease reclassification ( OR 4.3, 95% CI 1.25–14.73). Multivariate analysis showed that free testosterone and family history of PCa were independent predictors of disease reclassification. Conclusions: Free testosterone levels were lower in men with PCa who had reclassification during AS . Men with moderately severe reductions in free testosterone level are at increased risk of disease reclassification.


  • Association of a single-nucleotide polymorphism from chromosome 17q12 with the aggressiveness of prostate cancer in a Hispanic population

    by Pablo A. Rojas, Verónica Torres-Estay, Javier Cerda-Infante, Viviana P. Montecinos, Javier Domínguez, José Arenas, Alejandro S. Godoy, Ignacio F. San Francisco

    To study the association between the polymorphisms, rs1859962 and rs4430796, from the chromosomes 17q24 and 17q12, respectively, with the risk of prostate cancer (PCa) and its clinical characteristics in a Hispanic (Chilean) population. This study included 33 controls and 167 patients diagnosed with PCa. The polymorphisms, rs1859962 and rs4430796, were analyzed on blood specimens using quantitative PCR. The genetic analysis of the qPCR data was performed using the SNPStats program. A comparison between the clinical characteristics of the prostate cancers from the patients and the presence of the different polymorphism genotypes detected in blood specimens obtained from these patients was performed using the IBM SPSS v20.0 software. We observed no association of the SNPs and the risk of developing PCa (OR 0.84, 95 % CI 0.30–2.38, p = 1.0 to rs1859962 and OR 1.94, 95 % CI 0.57–6.52, p = 0.28 to rs4430796), both sporadic and hereditary. However, patients carrying the genotype G/G from the polymorphism rs4430796 had significantly higher PSA levels than patients carrying the other genotypes (15.05 ng/ml to G/G, 10 and 8.11 ng/ml to genotypes A/G y A/A, respectively, p = 0.01). Furthermore, patients with the genotype G/G of rs4430796 had higher tumor volume than other genotypes (9.45 cc to G/G and 5.22 cc to A/G + A/A, p = 0.04). The polymorphism rs4430796 of the chromosome 17q12 appears to be a biomarker for cancer aggressiveness, increased PSA and tumor volume of PCa.